Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, has signed an agreement with Vincci Hotels to offer health care to guests in all accommodations in Spain. The service includes 24/7 medical assistance, either by video call, in person or by a doctor’s visit in the hotel, if necessary. This service is offered in several languages to meet the demands from international guests.
Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, has signed an agreement with Vincci Hotels to offer health careto guests in all accommodations in Spain. The service includes 24/7 medical assistance, either by video call, in person or by a doctor’s visit in the hotel, if necessary. This service is offered in several languages to meet the demands from international guests.
Fresenius Medical Care North America and the health insurer Humana are broadening their collaboration. The goal is improved, better coordinated and more holistic care for eligible members, for example through expanded access to CKD care coordination services and transitional care units. In addition, the existing clinical network contract, which provides eligible members with access to dialysis at more than 2,600 Fresenius Kidney Care clinics, is being implemented as a value-based payment model. This means that reimbursement will be based on meeting agreed quality improvement and patient outcome goals.
Fresenius Medical Care, the world’s leading provider of products and services for people with chronic kidney failure, today announced publication of its 2020 Global Annual Medical Report. Titled “The Power of Ideas: Ingenuity, Optimism, and the Future of Global Healthcare,” it advances the worldwide conversation about the continuing evolution of healthcare and underlines the role Fresenius Medical Care can play in transforming care for chronically ill patients.
“This year’s report focuses on the ideas, ingenuity and optimism that are transforming healthcare,” said Franklin W. Maddux, MD, Global Chief Medical Officer of Fresenius Medical Care. “We look at ways to enhance patient choice, new frontiers in connected health, the promise of artificial intelligence, and other important topics including our global response to COVID-19. Our 2020 report also shows the remarkable diversity of people behind the ideas that are helping us evolve our healthcare systems to recognize the unique lifetime journey of each kidney disease patient.”
The 2020 Global Annual Medical Report comprises 24 chapters by nearly 40 authors from across the company, representing some of Fresenius Medical Care’s best thought leadership on a wide range of topics. These also include precision medicine and genomics, cardioprotective dialysis, value-based care, and transplantation.
Some of the key chapters include:
- Building on Lessons Learned: Activating a Global Pandemic Master Plan
- The Aspirational Role of Artificial Intelligence and Advanced Analytics
- The Power of Precision: Genomics Medicine and Power of Personalization of Kidney Care
- Cardioprotective Dialysis: Improving Cardiovascular Health Through More Personalized Treatment
- Driving Sustainability and Creating Value for Patients in Global Healthcare
- Increasing Access to Transplantation: Lessons from the United States
- Clinical Performance Supports Organized Value-Based Care
- Social Care and Medical Care Become Kidney Care
The 2020 Global Annual Medical Report is published by the Global Medical Office of Fresenius Medical Care. The full report is now available online at:
https://www.freseniusmedicalcare.com/en/about-us/sustainability/medical-responsibility/
Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.
The information and documents contained on the following pages of this website are for information purposes only. These materials do neither constitute an offer nor an invitation to subscribe to or to purchase securities, nor any investment advice or service, and are not meant to serve as a basis for any kind of obligation, contractual or otherwise. Securities may not be offered or sold in the United States of America (“US”) absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. The securities described on the following pages are not offered for sale in the US or to "US persons" (as defined in Regulation S under the US Securities Act of 1933, as amended).
THE FOLLOWING INFORMATION AND DOCUMENTS ARE NOT DIRECTED AT AND ARE NOT INTENDED FOR USE BY (I) PERSONS WHO ARE RESIDENTS OF OR LOCATED IN THE US, CANADA, JAPAN OR AUSTRALIA OR WHO ARE US PERSONS (AS DEFINED IN REGULATION S UNDER THE US SECURITIES ACT OF 1933, AS AMENDED), OR (II) PERSONS IN ANY OTHER JURISDICTION WHERE THE COMMUNICATION OR RECEIPT OF SUCH INFORMATION IS RESTRICTED IN SUCH A WAY THAT PROVIDES THAT SUCH PERSONS SHALL NOT RECEIVE IT. SUCH PERSONS, OR PERSONS ACTING FOR THE BENEFIT OF ANY SUCH PERSONS, ARE NOT PERMITTED TO VISIT THE FOLLOWING PAGES OF THE WEBSITE.
To visit the following parts of this website you must confirm that
(i) you are not a resident of the United States of America, Canada, Japan or Australia or a "US person" (as defined in Regulation S under the US Securities Act of 1933, as amended),
(ii) you are not a person to whom the communication of the information contained on the website is restricted,
(iii) you will not distribute any of the information and documents contained thereon to any such person, and
(iv) you are not acting for the benefit of any such person.
By clicking on the "Accept" button below, you will be deemed to have made this confirmation.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.
Fresenius today successfully placed bonds with an aggregate volume of €1.0 billion:
- €500 million bonds with a maturity in September 2026 and a coupon of 0.375% were issued at a price of 99.333% resulting in a yield of 0.488%,
- €500 million bonds with a maturity in January 2033 and a coupon of 1.125% were issued at a price of 99.738% resulting in a yield of 1.148%.
The proceeds will be used for general corporate purposes, including refinancing of existing financial liabilities.
The bonds were drawn under the Fresenius European Medium Term Note (EMTN) Program and issued by Fresenius SE & Co. KGaA. The company has applied to the Luxembourg Stock Exchange to admit the bonds to trading on its regulated market.
The envisaged settlement date is September 28, 2020.
This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in Australia, Canada, Japan, or the United States of America (the “United States”) or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to herein may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons, absent registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. The offer and sale of the securities referred to herein has not been and will not be registered under the Securities Act or under the applicable securities laws of Australia, Canada or Japan. There will be no public offer of the securities in the United States.
This announcement is a general information and not a prospectus. Investors should not purchase or subscribe for any securities referred to in this announcement except on the basis of information in the prospectus to be issued by the company in connection with the offering of such securities. Copies of the prospectus will, following publication, be available free of charge from Fresenius SE & Co. KGaA at Else-Kröner Strasse 1, 61352 Bad Homburg, Germany.
This announcement has been prepared on the basis that any offer of securities in any Member State of the European Economic Area (EEA) will be made pursuant to the prospectus prepared by Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company and Fresenius Finance Ireland II Public Limited Company in combination with the relevant final terms relating to such securities or pursuant to an exemption under Regulation (EU) 1129/2017 (the Prospectus Regulation) from the requirement to publish a prospectus for offers of securities. Neither Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company nor Fresenius Finance Ireland II Public Limited Company have authorized, nor do they authorize, the making of any offer of securities in circumstances in which an obligation arises for Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company and Fresenius Finance Ireland II Public Limited Company or any other person to publish or supplement a prospectus for such offer.
This announcement is directed at and/or for distribution in the United Kingdom only to (i) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (ii) high net worth entities falling within article 49(2)(a) to (d) of the Order (all such persons are referred to herein as “relevant persons”). This announcement is directed only at relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its contents. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.
This announcement contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Neither Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company nor Fresenius Finance Ireland II Public Limited Company undertake any responsibility to update the forward-looking statements in this announcement.
The information and documents contained on the following pages of this website are for information purposes only. These materials do neither constitute an offer nor an invitation to subscribe to or to purchase securities, nor any investment advice or service, and are not meant to serve as a basis for any kind of obligation, contractual or otherwise. Securities may not be offered or sold in the United States of America (“US”) absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. The securities described on the following pages are not offered for sale in the US or to "US persons" (as defined in Regulation S under the US Securities Act of 1933, as amended).
THE FOLLOWING INFORMATION AND DOCUMENTS ARE NOT DIRECTED AT AND ARE NOT INTENDED FOR USE BY (I) PERSONS WHO ARE RESIDENTS OF OR LOCATED IN THE US, CANADA, JAPAN OR AUSTRALIA OR WHO ARE US PERSONS (AS DEFINED IN REGULATION S UNDER THE US SECURITIES ACT OF 1933, AS AMENDED), OR (II) PERSONS IN ANY OTHER JURISDICTION WHERE THE COMMUNICATION OR RECEIPT OF SUCH INFORMATION IS RESTRICTED IN SUCH A WAY THAT PROVIDES THAT SUCH PERSONS SHALL NOT RECEIVE IT. SUCH PERSONS, OR PERSONS ACTING FOR THE BENEFIT OF ANY SUCH PERSONS, ARE NOT PERMITTED TO VISIT THE FOLLOWING PAGES OF THE WEBSITE.
To visit the following parts of this website you must confirm that
(i) you are not a resident of the United States of America, Canada, Japan or Australia or a "US person" (as defined in Regulation S under the US Securities Act of 1933, as amended),
(ii) you are not a person to whom the communication of the information contained on the website is restricted,
(iii) you will not distribute any of the information and documents contained thereon to any such person, and
(iv) you are not acting for the benefit of any such person.
By clicking on the "Accept" button below, you will be deemed to have made this confirmation.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.
Fresenius today successfully placed bonds with an aggregate volume of €1.0 billion:
- €500 million bonds with a maturity in September 2026 and a coupon of 0.375% were issued at a price of 99.333% resulting in a yield of 0.488%,
- €500 million bonds with a maturity in January 2033 and a coupon of 1.125% were issued at a price of 99.738% resulting in a yield of 1.148%.
The proceeds will be used for general corporate purposes, including refinancing of existing financial liabilities.
The bonds were drawn under the Fresenius European Medium Term Note (EMTN) Program and issued by Fresenius SE & Co. KGaA. The company has applied to the Luxembourg Stock Exchange to admit the bonds to trading on its regulated market.
The envisaged settlement date is September 28, 2020.
This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in Australia, Canada, Japan, or the United States of America (the “United States”) or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to herein may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons, absent registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. The offer and sale of the securities referred to herein has not been and will not be registered under the Securities Act or under the applicable securities laws of Australia, Canada or Japan. There will be no public offer of the securities in the United States.
This announcement is a general information and not a prospectus. Investors should not purchase or subscribe for any securities referred to in this announcement except on the basis of information in the prospectus to be issued by the company in connection with the offering of such securities. Copies of the prospectus will, following publication, be available free of charge from Fresenius SE & Co. KGaA at Else-Kröner Strasse 1, 61352 Bad Homburg, Germany.
This announcement has been prepared on the basis that any offer of securities in any Member State of the European Economic Area (EEA) will be made pursuant to the prospectus prepared by Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company and Fresenius Finance Ireland II Public Limited Company in combination with the relevant final terms relating to such securities or pursuant to an exemption under Regulation (EU) 1129/2017 (the Prospectus Regulation) from the requirement to publish a prospectus for offers of securities. Neither Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company nor Fresenius Finance Ireland II Public Limited Company have authorized, nor do they authorize, the making of any offer of securities in circumstances in which an obligation arises for Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company and Fresenius Finance Ireland II Public Limited Company or any other person to publish or supplement a prospectus for such offer.
This announcement is directed at and/or for distribution in the United Kingdom only to (i) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (ii) high net worth entities falling within article 49(2)(a) to (d) of the Order (all such persons are referred to herein as “relevant persons”). This announcement is directed only at relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its contents. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.
This announcement contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Neither Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company nor Fresenius Finance Ireland II Public Limited Company undertake any responsibility to update the forward-looking statements in this announcement.
The price increase for hospital services in Germany has been set at 2.53% for 2021. As it is subject to negotiations at the state level as well as individual hospital discounts, the final price increase on the individual hospital level will, however, be lower.
The price increase for hospital services in Germany has been set at 2.53% for 2021. As it is subject to negotiations at the state level as well as individual hospital discounts, the final price increase on the individual hospital level will, however, be lower.
Fresenius Medical Care, the world’s leading provider of dialysis products and services, has agreed to issue bonds with an aggregate principal amount of USD 1 billion. The bonds will mature in February 2031 and have an annual coupon of 2.375%. The issue price is 99.699%, resulting in a yield of 2.408%.
The proceeds will be used for general corporate purposes, including the refinancing of outstanding indebtedness.
The expected settlement date is September 16, 2020.
This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in Australia, Canada, Japan, or the United States of America (the “United States”) or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to herein have not been and will not be registered under U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons, absent such registration, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. The securities are being offered only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act and outside the United States, only to certain non-U.S. investors pursuant to Regulation S. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. The offer and sale of the securities referred to herein has not been and will not be registered under the applicable securities laws of Australia, Canada or Japan. There will be no public offer of the securities in the United States.
This announcement has been prepared on the basis that any offer of bonds in any Member State of the European Economic Area (each, a Member State) will only be made pursuant to an exemption under Regulation (EU) 2017/1129 (as amended, the “Prospectus Regulation”), from the requirement to publish a prospectus for offers of securities. Fresenius Medical Care has not authorized, nor does it authorize, the making of any offer of securities in circumstances in which an obligation arises for Fresenius Medical Care or any other person to publish or supplement a prospectus for such offer.
This announcement is directed at and/or for distribution in the United Kingdom only to persons who (i) are outside the United Kingdom; (ii) who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), (iii) are high net worth entities falling within article 49(2)(a) to (d) of the Order; or (iv) other persons to whom it may otherwise be lawfully communicated (all such persons together being referred to as “relevant persons”). This announcement is directed only at relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its contents. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.
This announcement contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. impacts of COVID-19, changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this announcement.
The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness. The information in this announcement is subject to change.
-
In his speech, Sturm underscored the important role Fresenius is playing in the current situation: "We are needed, and more than ever." Download Image (JPG 15 KB) -
![]()
Despite the strains caused by the pandemic and the additional effort required, Sturm confirmed the company’s medium-term outlook for 2020 to 2023. Download Image (JPG 91 KB) -
![]()
The AGM was held as a virtual meeting on the Internet in order to protect the health of all participants. Download Image (JPG 5.19 MB) -
![]()
Sturm: "We help ensure that healthcare systems around the world can continue to function. Even in a crisis such as this." Download Image (JPG 7.39 MB)
Fresenius remains on course for growth, even in the face of significant challenges presented by the COVID-19 pandemic. This was confirmed by Chief Executive Officer Stephan Sturm at the global healthcare group’s Annual General Meeting today. Originally scheduled for May, the AGM was held as a virtual meeting on the Internet in order to protect the health of all participants.
In his speech to shareholders, Sturm underlined Fresenius’ important role in the current situation: “We are needed – more than ever. We help ensure that healthcare systems around the world can continue to function. Even in a crisis such as this. We are doing everything we can to provide the best possible care for patients. This is our responsibility, and we will fulfill it. I am proud of that.”
Despite the strains caused by the pandemic and the additional effort required, Sturm confirmed the company’s medium-term outlook for 2020 to 2023. Sales growth is expected to increase by an annual average of 4 to 7 percent and net income growth1 by an annual average of 5 to 9 percent over this period. “We will grow somewhat less than planned this year due to the coronavirus,” said Sturm. “This must be compensated for in the coming years. I believe we are on the right path. There is no reason to diverge from this goal. The need for high-quality medicine is increasing worldwide. We offer high-quality medicine. We want to serve this demand, and we can. That is why we will continue to be successful.”
1 Net income attributable to shareholders of Fresenius SE & Co. KGaA
Shareholders approved with a large majority of 99.99 percent the proposal of the General Partner and the Supervisory Board to increase the dividend for the 27th consecutive time. It was raised by 5 percent, to €0.84 per share.
Shareholder majorities of 99.68 percent and 85.14 percent, respectively, approved the actions of the Management and Supervisory Boards in 2019.
At the virtual Annual General Meeting, 73 percent of the subscribed capital was represented.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.